Aardvark Therapeutics, Inc.

There were six initial public offerings by biopharmaceutical companies on Western stock exchanges during the first quarter of 2025, up from four in the fourth quarter of 2024, but all of the IPOs occu

Soleno Therapeutics has gained US approval for Vykat XR, making it the first ever drug to treat hyperphagia, an intense, persistent hunger experienced by people with the rare genetic disorder Prader-W

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

A thriving market for initial public offerings is essential for biopharmaceutical industry growth as firms seek to expand drug development programs beyond the scope of what their venture capital backe